The Fight Against COVID19
13.22k followers • 13 symbols Watchlist by TREA
Follow this list to discover and track the stock of publicly traded companies with COVID-19 related treatment and healthcare plans.
Curated by TREA
Performance
| Watchlist | Change today | 1-month return | 1-year return | Total return |
|---|---|---|---|---|
| The Fight Against COVID19 | -0.04% | - | - | - |
| ^GSPC | +0.36% | +3.99% | +16.23% | +3455.39% |
13 symbols
| Symbol | Company name | Last price | Change | % change | Market time | Volume | Avg vol (3-month) | Market cap |
|---|---|---|---|---|---|---|---|---|
| JNJ | Johnson & Johnson | 147.22 | -0.13 | -0.09% | 4:00 pm GMT-4 | 4.03M | 6.95M | 387.60B |
| PFE | Pfizer Inc. | 38.39 | +0.04 | +0.10% | 4:02 pm GMT-4 | 22.66M | 31.40M | 213.25B |
| ABBV | AbbVie Inc. | 94.29 | -1.65 | -1.72% | 4:02 pm GMT-4 | 7.61M | 9.32M | 169.08B |
| SNY | Sanofi | 51.79 | -1.42 | -2.67% | 4:00 pm GMT-4 | 1.27M | 1.38M | 129.75B |
| GSK | GlaxoSmithKline plc | 41.24 | -0.05 | -0.12% | 4:00 pm GMT-4 | 2.18M | 3.16M | 100.28B |
| GILD | Gilead Sciences, Inc. | 70.88 | -0.85 | -1.19% | 4:00 pm GMT-4 | 9.11M | 10.21M | 88.91B |
| REGN | Regeneron Pharmaceuticals, Inc. | 648.43 | +3.25 | +0.50% | 4:00 pm GMT-4 | 747.93k | 1.27M | 66.53B |
| TAK | Takeda Pharmaceutical Company Limited | 18.37 | -0.15 | -0.81% | 4:00 pm GMT-4 | 761.98k | 1.14M | 56.95B |
| MRNA | Moderna, Inc. | 78.46 | +0.48 | +0.62% | 4:00 pm GMT-4 | 9.35M | 26.92M | 28.95B |
| BNTX | BioNTech SE | 83.17 | -2.30 | -2.69% | 4:00 pm GMT-4 | 2.41M | 2.87M | 19.81B |
| NVAX | Novavax, Inc. | 157.17 | +1.30 | +0.83% | 4:00 pm GMT-4 | 11.52M | 9.53M | 9.15B |
| VIR | Vir Biotechnology, Inc. | 50.6 | +1.08 | +2.18% | 4:00 pm GMT-4 | 358.04k | 1.47M | 6.39B |
| INO | Inovio Pharmaceuticals, Inc. | 20.315 | -0.38 | -1.81% | 4:00 pm GMT-4 | 10.56M | 35.97M | 3.21B |
- Motley Fool
Novavax's Coronavirus Vaccine Induced Antibodies in 100% of Phase 1 Trial Participants
Novavax (NASDAQ: NVAX) is trailing the leaders in the race to develop the first vaccine to protect against the novel coronavirus that causes COVID-19. In the phase 1 portion of the phase 1/2 clinical trial, two doses of NVX-CoV2373 induced neutralizing antibodies in every volunteer in the study. Neutralizing antibodies are capable of blocking infection by the coronavirus in laboratory tests and hopefully will protect patients from developing COVID-19 if they're exposed to the coronavirus, although Novavax doesn't have any data on the latter yet.
- Zacks
3 Diverse Large-Cap Stocks to Buy Now to Boost Your Long-Term Portfolio
Investors should consider adding a few large-cap names that are prepared to grow for years to come. These three stocks also pay dividends and provide exposure to three very different and vital industries...
- Motley Fool
Eli Lilly's COVID-19 Treatment Candidate Will Be the First Tested in NIH's Phase 3 Study
The National Institutes of Health is starting a head-to-head trial of several antibody treatment candidates.
